dimethylpelargonate, β-(p-methyl-cyclohexyl)propionate, β-(p-ethyl-cyclohexyl)-propionate, β-(cycloheptyl)-propionate, α-methyl-β-cyclohexyl-propionate, β-methyl-β-cyclohexyl-propionate, cyclododecyl-carboxylate, adamantine-1'-carboxylate, adamant-1'-yl-acetate, methyl-β-cyclohexyl-propionate, and β-(bicyclo-[2,2,2]-oct-1'-yl)-propionate esters. Suitable lipoidal vehicles for enhancing the oral activity of the aforementioned esters are oils, e.g., arachis oil, castor oil, sesame oil, linseed oil, soya bean oil, sunflower seed oil, olive oil, fish liver oil, ethyl oleate, oleyl oleate, glyceryl trioleate, glyceryl dioleate, glyceryl monooleate, and oleic acid.

A1

IN THE CLAIMS:

Cancel claims 40-42 and 51-54 without prejudice.

Amend claims 1, 25-29, 43, and 48-50 as indicated in Appendix A. The amended claims will then read as follows:

Sub B2

1. (Amended) A method for enhancing sexual desire and responsiveness in a female individual, comprising: (a) orally administering to the individual a therapeutically effective amount of an orally active androgenic agent as a first active agent; and optionally (b) administering to the individual a therapeutically effective amount of a second active agent selected from the group consisting of vasoactive agents, rho kinase inhibitors, melanocortin peptides, endothelin antagonists, growth factors and other peptidyl drugs, selective androgen receptor modulators (SARMs), neuropeptides, amino acids, serotonin agonists, serotonin antagonists, calcium channel blockers, potassium channel openers, potassium channel blockers, non-androgenic steroids, and combinations thereof, wherein administration is on an as-needed basis.

A2

Sub B2 Cont

25. (Amended) The method of claim 1, wherein the therapeutically effective amount of the second active agent is administered.

A3

26. (Amended) The method of claim 25, wherein the second active agent is administered with the androgenic agent.

27. (Amended) The method of claim 25, wherein the second active agent is administered prior to administration of the androgenic agent.

28. (Amended) The method of claim 25, wherein the second active agent is administered after administration of the androgenic agent.

29. (Amended) The method of claim 25, wherein the second active agent is a vasoactive agent.

43. (Amended) The method of claim 25, wherein administration of the second active agent is topical, transdermal, sublingual, intranasal, buccal, rectal, parenteral, or by inhalation.

48. (Amended) A method for preventing vaginal pain during sexual intercourse, comprising orally administering to a female individual suffering from dyspareunia a therapeutically effective amount of an orally active androgenic agent on an as-needed basis.

49. (Amended) A method for alleviating vaginal itching and dryness, comprising orally administering to a female individual in need of such treatment a therapeutically effective amount of an orally active androgenic agent on an as-needed basis.

50. (Amended) A method for enhancing sexual desire and responsiveness in a female individual, comprising orally administering an orally active androgenic agent to the individual in an amount effective to provide a blood level of the agent or a metabolite thereof that approximates the blood level of the agent or a metabolite thereof during ovulation, wherein said administering is carried out on an as-needed basis.

Also add new claim 55, as follows:

55. A method for enhancing sexual desire and responsiveness in a female individual, consisting essentially of orally administering to the individual a therapeutically effective amount of an orally active androgenic agent on an as-needed basis.